KEY DETAILS
Most states are rejecting Trump's Medicaid discount, limiting Wegovy access for the poor.
The Trump administration offered state Medicaid programs a discount on weight-loss drugs like Wegovy, hoping to expand coverage for low-income patients. Most states have turned the offer down. Officials in both red and blue states say the deal would still cost too much, even with federal help. That decision leaves many Medicaid patients without a clear path to these medications, at least for now.
The offer was meant to make drugs such as Wegovy more affordable for people covered by Medicaid, one of the largest sources of health coverage for low-income Americans. Despite that goal, most states have declined to sign on, citing the ongoing cost of covering these medications even at a reduced rate. Governors from both parties have raised the same concern: state budgets are already stretched, and a long-term commitment to subsidize weight-loss drugs feels risky. As a result, many Medicaid patients who might benefit from these treatments will continue to face limited or no coverage. For now, access largely depends on which state a patient lives in, rather than on medical need alone.
If you rely on Medicaid, it is reasonable to check with your state's program directly, since coverage decisions are changing state by state and may shift again as more information comes in. Either way, I would suggest confirming the details with your own doctor and your own state's Medicaid office before making any changes to your treatment plan.
Read this on GLP-1 Nation: https://glp1nation.com/edition/28